Imugene Posts Strong Azer-cel Data and Cuts Costs as It Advances Toward Pivotal Trial

Imugene ( (AU:IMU) ) has issued an update.

Imugene reported strong Phase 1b clinical data for its allogeneic CD19 CAR T therapy azer-cel, achieving an 82% overall response rate in relapsed/refractory DLBCL, including seven complete and seven partial responses among 17 patients, with the first patient dosed in 2024 remaining cancer-free for more than 21 months and an 83% response rate recorded in a CAR T–naïve cohort of heavily pre-treated lymphoma patients. The company also highlighted regulatory and strategic milestones, including favourable FDA meeting minutes providing a pathway to a pivotal azer-cel trial, selection of azer-cel for an oral presentation at the ASH Annual Meeting, a new collaboration with JW Therapeutics to advance its onCARlytics program, amendments to convertible notes to improve cash flow, and expectations that operating costs will be about 50% lower than the prior financial year, collectively strengthening its clinical and financial positioning.

The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.32 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.

More about Imugene

Imugene Limited is an ASX-listed, clinical-stage immuno-oncology company focused on developing novel cancer therapies, including allogeneic, off-the-shelf CAR T cell treatments, targeting difficult-to-treat malignancies such as relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Average Trading Volume: 1,331,904

Technical Sentiment Signal: Sell

Current Market Cap: A$110.3M

See more data about IMU stock on TipRanks’ Stock Analysis page.